+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Congenital Hyperinsulinism - Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Hyperinsulinism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Argininosuccinic Aciduria - Pipeline Insight, 2025 - Product Thumbnail Image

Argininosuccinic Aciduria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
MPYS Protein Stimulants - Pipeline Insight, 2025 - Product Thumbnail Image

MPYS Protein Stimulants - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
PRMT5 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PRMT5 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
DUX4 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

DUX4 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
WEE1 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

WEE1 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Krabbe Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Krabbe Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
MPYS Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

MPYS Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Bardet-Biedl Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Bardet-Biedl Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Central Precocious Puberty - Pipeline Insight, 2025 - Product Thumbnail Image

Central Precocious Puberty - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hunter Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025 - Product Thumbnail Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Familial Chylomicronemia Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Familial Chylomicronemia Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hyperparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Hyperparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Proteus Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Proteus Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Niemann Pick C Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Niemann Pick C Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more